Formulations that can be administered as a total dose in a single infusion are indicated in bold.

LMW indicates low molecular weight.

* Approved only in chronic kidney disease patients.

† FDA black box warning advices slow administration of the drug and observation of patients for 30 minutes post-infusion.

‡ Availability of the products may differ in different countries, eg, licensed only in Europe.

Adapted from Camaschella.¹⁴